Pipeline of Drugs ... very light in CanadaThanks again for the clarification on the pipeline information.
The pipeline makes one thing clear ... we have no prospects for Canada at pre-approval.
We do have fairly new revenue generators in Canada though ... Imvexxy, Bijuva and Exelon.
We are sitting at 11 actual DrugxCountries in our pipeline:
Tafasitamab x 5 countries (all but Canada)
Pemigatinib x 5 countries (all but Canada)
Halaven - Columbia - thyroid
Approvals are now the early-stage revenue generators at Knight and we have
10 DrugxCountries here:
Imvexxy - Canada
Bijuva - Canada
Halaven - Columbia - breast
Lenvima - Columbia
Exelon - 6 geographies (though marketed, Exelon is in early stage sales for Knight - unique situation)